Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc. to Release Fiscal 2023 Second Quarter Earnings Results

Retrieved on: 
Tuesday, October 4, 2022
Investor relations, Compound, NYSE, PBH, Prestige Consumer Healthcare, Company, GLOBE, Pharmaceutical industry

TARRYTOWN, N.Y., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2023 second quarter earnings release on Thursday, November 3, 2022 before the opening of the market.

Key Points: 
  • TARRYTOWN, N.Y., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2023 second quarter earnings release on Thursday, November 3, 2022 before the opening of the market.
  • The Company will host a conference call to discuss the results that same morning at 8:30 a.m.
  • To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com .
  • AboutPrestige Consumer Healthcare Inc.
    Prestige Consumer Healthcaremarkets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout theU.S.andCanada,Australia, and in certain other international markets.

NUFABRX® APPOINTS NEW BOARD MEMBERS

Retrieved on: 
Wednesday, September 14, 2022
W. L. Gore & Associates, Health, Target, Walmart, Gore-Tex, Textile, Prestige Consumer Healthcare, Oregon State University, LLC, Research, American Institute, Knowledge, Director, Pains, Compliance, Growth, CPG, Industry, Advisory board, Jason Fields, Elise, CEO, Arizona State University, Technology, BOARD, Quality of life, Board of directors, Clothing, Doctor of Philosophy, Leadership, AdvaMed, Veterinary medicine, CVS, Vitamin, Board, PC, Jenny Craig, Inc., LA, Multimedia, Education, University, Former, Management, 3D printing, Airborne, Walgreens, Associate

 CONOVER, N.C., Sept. 14, 2022 /PRNewswire/ -- Nufabrx®, an innovative North Carolina-based platform technology company, is proud to announce the addition of Dr. Jason Field to their Board of Directors and to welcome new Advisory Board Member Elise Donahue. Nufabrx® is known for their groundbreaking technology to simplify patient compliance, focused on the controlled delivery of active ingredients (vitamins, supplements, and medications) through clothing. The company has grown to national retail distribution, including the world's largest retailer, Walmart, as well as Target, CVS, Walgreens, and numerous others.

Key Points: 
  • Nufabrx is known for their groundbreaking technology to simplify patient compliance, focused on the controlled delivery of active ingredients (vitamins, supplements, and medications) through clothing.
  • NUFABRX APPOINTS NEW BOARD MEMBERS to rapidly growing mission of simplifying health, wellness and patient compliance
    "We are honored and elated to have both Dr. Jason Field and Elise Donahue join the Nufabrx Team," stated Nufabrx Founder & CEO Jordan Schindler.
  • She has also served as Board of Directors at Jenny Craig during its heyday, and at LA Fitness-Europe.
  • HealthWear, pioneered by Nufabrx, is a market category that integrates medication and textiles to create wearable clothing and simplify health and wellness for consumers.

Prestige Consumer Healthcare to Present at Barclays Global Consumer Staples Investor Conference

Retrieved on: 
Wednesday, September 7, 2022
PBH, NYSE, GLOBE, Company, Compound, Prestige Consumer Healthcare, Pharmaceutical industry

TARRYTOWN, N.Y., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) will present at the 2022Barclays Global Consumer Staples Conferenceon Thursday, September 8, 2022at12:45 p.m.

Key Points: 
  • TARRYTOWN, N.Y., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) will present at the 2022Barclays Global Consumer Staples Conferenceon Thursday, September 8, 2022at12:45 p.m.
  • ET.
  • About Prestige Consumer Healthcare Inc.
    Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets.
  • Visit the Company's website at www.prestigeconsumerhealthcare.com.

Audax Private Equity Completes the Sale of WellSpring Consumer Healthcare to Avista Capital Partners

Retrieved on: 
Tuesday, August 23, 2022
General Health, Finance, Other Health, Health, Professional Services, Partnership, Consumer, Audax, Prestige Consumer Healthcare, Sale, LinkedIn, Industry, Wellspring, FDS, Miconazole, Company, Avista Capital Partners, Skin care, Private equity, Bactine, Ropes & Gray, Growth, Marketing, Financial services

Audax Private Equity (Audax) today announced that it has completed the sale of WellSpring Consumer Healthcare (WellSpring or the Company) to Avista Capital Partners.

Key Points: 
  • Audax Private Equity (Audax) today announced that it has completed the sale of WellSpring Consumer Healthcare (WellSpring or the Company) to Avista Capital Partners.
  • Since its founding in 1999, the firm has raised over $30 billion in capital across its Private Equity and Private Debt businesses.
  • Founded in 1999, WellSpring Pharmaceutical Corporation is a privately held company focused on the development and marketing of consumer healthcare products.
  • The company markets numerous trusted over-the-counter and personal care brands in the United States and Canada through its consumer products unit, WellSpring Consumer HealthCare.

European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive Candidiasis

Retrieved on: 
Monday, August 22, 2022
Infectious Diseases, FDA, Marketing, Communications, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Caspofungin, Mortality, European Medicines Agency, Treatment, EMA, NDA, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, View, Therapy, Prestige Consumer Healthcare, Candidiasis, Integrity, Disease, US Foods, QIDP, Heart, Global, MAA, New Drug Application, Hope, Food, Â, Hospital, Mycosis, Community, Medicine, Priority review, FDA, Pain management, Pivotal, Adult, Food and Drug Administration, The New England Journal of Medicine, Jean-Louis Vincent, European Commission, Patient, Pharmaceutical industry, Medical imaging, Restore, EU, Fungemia, Mundipharma

Mundipharma today announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adult patients.

Key Points: 
  • Mundipharma today announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for rezafungin for the treatment of invasive candidiasis in adult patients.
  • Rezafungin, as a next generation echinocandin, represents the first advancement in the treatment of invasive Candida infections in a very long time.
  • We are pleased that the EMA has accepted our marketing authorisation application for rezafungin, and we look forward to working with the EMA to bring this medicine to patients.
  • 6 Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis.

PM360 Announces 2022 Trailblazer Award Finalists

Retrieved on: 
Wednesday, August 17, 2022
Slate, People, Rotavirus vaccine, 360, Leadership, Epsilon, Swoop, Syneos Health, Commercial, Gaming the system, System, Abbott, Communication, Merck, Marketing, Hear Our Voice, Scar, Horizon Therapeutics, Decision-making, Novartis, Psychological warfare, Alzheimer's disease, BCW, GO, Disease, GlaxoSmithKline, Boehringer Ingelheim, Diversity, Eli Lilly and Company, PR, GSW, Prestige Consumer Healthcare, AstraZeneca, Snow, Heart failure, AI, CRM, Company, Management, Pharmaceutical industry, Medical device, Spice, Public relations, Narcolepsy, Pain

NEW YORK, Aug. 17, 2022 /PRNewswire/ -- PM360 has announced the finalists for its 14th annual Trailblazer Awards. PM360, a leading life sciences marketing industry trade publication, established the Trailblazer Awards in 2009 to recognize and honor outstanding companies, marketers, marketing teams, brand managers, and initiatives that have demonstrated innovation and achieved incredible results in the life sciences.

Key Points: 
  • Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.
  • The journal's targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership.
  • Additionally, the "360" in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.
  • By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi

Retrieved on: 
Tuesday, July 12, 2022
Prestige Consumer Healthcare, Anxiety, Permira, Acquisition, Degenerative disease, Solution, Psychiatry, Awareness, Central nervous system disease, Parkinson's disease, Patient, CEO, Depression, Myasthenia gravis, Population, EUR, Mental health, Pain, Central nervous system, Parkinson, Neurological disorder, Growth, CNS, Neurology, Psychosis, Fine chemical, Pharmaceutical industry, Sanofi

DUSSELDORF, Germany and BARCELONA, Spain, July 12, 2022 /PRNewswire/ -- Neuraxpharm Group ("Neuraxpharm") today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi. With the upcoming acquisition, Neuraxpharm will strengthen its position as a leading European specialty pharmaceutical company focused on CNS. The well-established products that Neuraxpharm will acquire are marketed globally in more than 50 countries.

Key Points: 
  • With the upcoming acquisition, Neuraxpharm will strengthen its position as a leading European specialty pharmaceutical company focused on CNS.
  • The well-established products that Neuraxpharm will acquire are marketed globally in more than 50 countries.
  • The first portfolio combines 15 products addressing CNS disorders and ranging across psychiatry and neurology.
  • Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites, Lesvi and Inke, in Spain.

Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi

Retrieved on: 
Tuesday, July 12, 2022
Prestige Consumer Healthcare, Anxiety, Permira, Acquisition, Degenerative disease, Solution, Psychiatry, Awareness, Central nervous system disease, Parkinson's disease, Patient, CEO, Depression, Myasthenia gravis, Population, EUR, Mental health, Pain, Central nervous system, Parkinson, Neurological disorder, Growth, CNS, Neurology, Psychosis, Fine chemical, Pharmaceutical industry, Sanofi

DUSSELDORF, Germany and BARCELONA, Spain, July 12, 2022 /PRNewswire/ -- Neuraxpharm Group ("Neuraxpharm") today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi. With the upcoming acquisition, Neuraxpharm will strengthen its position as a leading European specialty pharmaceutical company focused on CNS. The well-established products that Neuraxpharm will acquire are marketed globally in more than 50 countries.

Key Points: 
  • With the upcoming acquisition, Neuraxpharm will strengthen its position as a leading European specialty pharmaceutical company focused on CNS.
  • The well-established products that Neuraxpharm will acquire are marketed globally in more than 50 countries.
  • The first portfolio combines 15 products addressing CNS disorders and ranging across psychiatry and neurology.
  • Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites, Lesvi and Inke, in Spain.

Prestige Consumer Healthcare Inc. to Release Fiscal 2023 First Quarter Earnings Results

Retrieved on: 
Monday, July 11, 2022
PBH, ID, Investor relations, NYSE, Company, Compound, Prestige Consumer Healthcare, GLOBE, Video game, Pharmaceutical industry

TARRYTOWN, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2023 first quarter earnings release on Thursday, August 4, 2022 before the opening of the market.

Key Points: 
  • TARRYTOWN, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2023 first quarter earnings release on Thursday, August 4, 2022 before the opening of the market.
  • The Company will host a conference call to discuss the results that same morning at 8:30 a.m.
  • To participate in the conference call via phone, listeners calling from the U.S. and Canada may dial 833-634-2598, or 412-902-4108 internationally, and reference joining the Prestige Consumer Healthcare earnings call.
  • AboutPrestige Consumer Healthcare Inc.
    Prestige Consumer Healthcaremarkets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout theU.S.andCanada,Australia, and in certain other international markets.

Ascential Digital Commerce and GSK Consumer Healthcare Announce Launch of Ascential Digital Commerce Connect at Cannes Lions

Retrieved on: 
Tuesday, June 14, 2022
Home Goods, Search Engine Optimization, Retail, Search Engine Marketing, Data Management, Other Communications, Other Health, Technology, Marketing, Advertising, Communications, Online Retail, Software, Internet, Health, Medical Supplies, Prestige Consumer Healthcare, Marketing, IDC, Paracetamol, Research, Centrum, Health care, CEO, Creativity, Multimedia, GlaxoSmithKline, Cannes Lions International Festival of Creativity, Tonian, E-commerce, Growth, Patient, Diclofenac, Technology, Health, EMEA, London Stock Exchange, Financial services, Ali Baba, Digital, Connect, Industry, GSK, Ascential, London, Sensodyne, Amazon, Product design, Online shopping, Nasdaq

Ascential Digital Commerce , whose technology driven products power brands to win in digital commerce, and GSK Consumer Healthcare , a science-led healthcare company, will join forces on June 20th during the Cannes Lions International Festival of Creativity to launch Ascential Digital Commerce Connect, a first-of-its-kind, data-rich, digital commerce platform that provides C-suite executives with visibility of brand sales and performance from multiple data sources.

Key Points: 
  • Ascential Digital Commerce , whose technology driven products power brands to win in digital commerce, and GSK Consumer Healthcare , a science-led healthcare company, will join forces on June 20th during the Cannes Lions International Festival of Creativity to launch Ascential Digital Commerce Connect, a first-of-its-kind, data-rich, digital commerce platform that provides C-suite executives with visibility of brand sales and performance from multiple data sources.
  • Ascential Digital Commerce Connect improves reaction time to market dynamics, increasing a brand's performance in the rapidly growing eCommerce retail market.
  • View the full release here: https://www.businesswire.com/news/home/20220610005544/en/
    Ascential Digital Commerce and GSK Consumer Healthcare partnered together to develop Ascential Digital Commerce Connect to provide visibility and clarity of GSK Consumer Healthcare's eCommerce brands performance, improve reaction time to market dynamics and position the brand for further growth.
  • During Cannes Lions 2022, Ascential Digital Commerce and GSK Consumer Healthcare will host a panel discussion to discuss the catalyst for developing Ascential Digital Commerce Connect and how GSK Consumer Healthcare currently leverages the platform for brand success.